Formulation & Concentration
Novoeight®, Antihemophilic Factor (Recombinant) For Intravenous Injection. Lyophilized Powder for Solution Initial

Manufacturer
Novo Nordisk

Indications
Novoeight is indicated for use in adults and children with hemophilia A for the control and prevention of bleeding, perioperative management, and routine prophylaxis to prevent or reduce the frequency of bleeding episodes.

Novoeight® is not indicated for the treatment of von Willebrand disease.

Vial Size NDC #
250 IU 0169-7825-01
500 IU 0169-7850-01
1000 IU 0169-7810-01
1500 IU 0169-7815-01
2000 IU 0169-7820-01
3000 IU 0169-7830-01

Shelf Life
Refrigerated up to thirty (30) months

Room temperature up to twelve (12) months
Storage
Store Novoeight under refrigeration at a temperature of 36°F-46°F (2°C – 8°C). Novoeight may also be stored at room temperature not to exceed 86°F (30°C).